{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Padilha EC"],"funding":["Fundação de Amparo à Pesquisa do Estado de São Paulo","NIAMS NIH HHS"],"pagination":["234"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6491728"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["Currently no approved treatment exists for fibrodysplasia ossificans progressiva (FOP) patients, and disease progression results in severe restriction of joint function and premature mortality. LDN-193189 has been demonstrated to be efficacious in a mouse FOP disease model after oral administration. To support species selection for drug safety evaluation and to guide structure optimization for back-up compounds, <i>in vitro</i> metabolism of LDN-193189 was investigated in liver microsome and cytosol fractions of mouse, rat, dog, rabbit, monkey and human. Metabolism studies included analysis of reactive intermediate formation using glutathione and potassium cyanide (KCN) and analysis of non-P450 mediated metabolites in cytosol fractions of various species. Metabolite profiles and metabolic "],"journal":["Frontiers in pharmacology"],"pubmed_title":["Application of <i>in vitro</i> Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)."],"pmcid":["PMC6491728"],"funding_grant_id":["R01 AR057374"],"pubmed_authors":["McKew J","Mutlib A","Lee A","Kerns E","Peccinini RG","Huang W","Padilha EC","Sanderson P","Xu X","Wang J","Yu PB","Jiang JK"],"additional_accession":[]},"is_claimable":false,"name":"Application of <i>in vitro</i> Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).","description":"Currently no approved treatment exists for fibrodysplasia ossificans progressiva (FOP) patients, and disease progression results in severe restriction of joint function and premature mortality. LDN-193189 has been demonstrated to be efficacious in a mouse FOP disease model after oral administration. To support species selection for drug safety evaluation and to guide structure optimization for back-up compounds, <i>in vitro</i> metabolism of LDN-193189 was investigated in liver microsome and cytosol fractions of mouse, rat, dog, rabbit, monkey and human. Metabolism studies included analysis of reactive intermediate formation using glutathione and potassium cyanide (KCN) and analysis of non-P450 mediated metabolites in cytosol fractions of various species. Metabolite profiles and metabolic ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2026-04-08T03:17:41.137Z","creation":"2019-06-06T23:09:35Z"},"accession":"S-EPMC6491728","cross_references":{"pubmed":["31068801"],"doi":["10.3389/fphar.2019.00234"]}}